Exscientia, the company leading the use of Artificial Intelligence (AI) in drug discovery, announces that is has acquired the biophysics specialists, Kinetic Discovery, a private UK company. The acquisition builds up Exscientia’s capabilities for the tackling novel drug targets to create first-in-class drug candidates by seeding its algorithms with data generated through the use of fragment screening and structural biology. The addition of Kinetic’s complementary expertise enables Exscientia to create a “full stack” AI-driven drug discovery company to go rapidly from gene to clinical candidate for any druggable target of choice. The acquisition of Kinetic is part of Exscientia’s growth strategy to develop a proprietary drug pipeline and to enhance its support of existing and future partnerships.
Facilities in The Schrödinger Building to bring together AI experts and biologists
Oxford, UK, 1 November 2018 - In a key point in its growth strategy, Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is expanding its Oxford presence to the new Schrödinger Building on The Oxford Science Park, one of the UK's leading parks for science and technology companies. In its new facilities, Exscientia is bringing together its computer scientists, drug designers and biologists under one roof to allow it to rapidly expand its platform development and proprietary drug discovery portfolio. The move also allows the firm to expand its recruitment activities in Oxford. Exscientia is the third occupant of The Oxford Science Park’s new Schrödinger Building, and it expects to move in by the end of the year.
Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that its COO Mark Swindells has been selected to join an elite group of companies invited to present at the Numis T500 Conference (Tuesday 10th - Thursday 12thJuly 2018) at Numis Securities,London. Dr Swindells will be accompanied by Exscientia Chairman Alex Snow
Dr Swindells will provide an overview of the Company and the significant progress it has made over the last few years in a presentation to invited investors and discuss Exscientia’s strategies for growth on Tuesday 10thJuly. In 2017 the Company announced collaborations with GSK and Sanofi as well as a significant investment from Evotec.
Numis Venture Broking is set to host the first T500 conference, connecting its 400 top investors (T400) with its top 100 companies (T100). More information is available here: https://www.numiscorp.com/x/t500.html
Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches.
Exscientia’s innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by its AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes.
By applying a rapid design-make-test cycle, the Exscientia AI platform actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria.
Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria.
As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.
Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi and GSK.
Exscientia, is delighted to note that its Chief Chemist Andy Bell, who previously led a medicinal chemistry team at Imperial College, has published ground-breaking work that identifies novel molecules to treat the common cold.
The research, published in Nature Chemistry, describes work behind the design of IMP-1088, a novel and highly potent anti-viral that prevents the cold virus from making new copies of itself. By targeting a human protein (N-myristoyltransferase) rather than a cold virus protein, the emergence of drug resistance to IMP-1088 is expected to be minimised. Further research leading to human clinical trials is anticipated.
To learn more, see the announcement by Imperial College and the original publication.
Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce the opening of its new offices in central Oxford, UK, in the UK’s most dynamic life science cluster.
Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is delighted to announce success at the 2017 Courier Awards, held in Dundee and organised by D.C. Thomson, a leading British publishing house.